AI Driven Precision in Predicting and Treating Hematologic Cancer

Hematological cancers, such as leukemias, lymphomas and myelomas, manifest from blood-forming tissues and their prognosis largely depends on both the cancer subtype and its stage at the time of detection. These cancers, characterized by subtle and non-specific initial symptoms, are quite difficult to diagnose in their early stages, although early identification is critical to optimize treatment success and improve survival prospects. In 2020, approximately 1.2 million people were fighting these blood cancers or were in remission, representing an alarming 9.5% of newly diagnosed cancer cases in the United States (1)(2). Survival rates vary widely, from around 60% in leukemias to more than 85% in specific lymphomas, emphasizing the dire need for timely and accurate detection and treatment (3)(4).

• Hematological cancers are difficult to diagnose early due to subtle and non-specific symptoms.
• In 2020, 9.5% of new cancer cases in the U.S. were hematological cancers, affecting 1.2 million people.
• Survival rates vary: about 60% for leukemias and over 85% for certain lymphomas.

"HemaSupport AI”, A conversational AI assistant to provide decision support based on the most current research and clinical guidelines.

Integrates guidelines from the European Hematology Association (5), which detail care standards, findings from Allart-Vorelli et al. (6) on quality of life in blood cancer, and NICE directives (7).